ENGINEERING CELL TYPE SPECIFIC TOXINS

工程细胞类型特异性毒素

• 批准号: 6111851
• 负责人: RICHARD J. YOULE
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6111851
• 关键词: AIDS therapy; CD4 molecule; antiAIDS agent; brain neoplasms; cytotoxicity; endoribonucleases; genetic manipulation; human tissue; immunoconjugates; immunotoxicity; molecular cloning; monoclonal antibody; neoplasm /cancer immunotherapy; neurotoxins; pancreatic ribonuclease; protein engineering; tumor antigens

Monoclonal antibodies selectively bind tumor cell differentiation antigens in vitro and in vivo. Since natural effector mechanisms often do not mediate killing of monoclonal antibody bound cells we have devised methods of linking extremely toxic proteins to the antibodies to selectively kill tumor cells. We have succeeded in developing several new approaches to apply immunotoxins in vivo. (1) Cloning toxins, then altering their structure at the gene level to decrease non-target cell toxicity; (2) use of human cytotoxic proteins such as RNase linked to antibodies to selectively target cells; 3) understanding the mechanism of human RNase neurotoxins; and (4) discovering that RNases block HIV infection in vivo.

单克隆抗体选择性结合肿瘤细胞